Events Archives - Page 15 of 128

1 minute read

Leap Therapeutics To Present New Data From Part A Of The DeFianCe Study Of DKN-01 Plus Bevacizumab And Chemotherapy In Colorectal Cancer Patients At The 2024 ASCO Gastrointestinal Cancers Symposium

December 11, 5:12 PM

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients

LPTX

5 minute read

MEI Pharma Reports Clinical Data On Oral CDK9 Inhibitor Voruciclib At ASH2023

By Benzinga Newsdesk

December 11, 1:06 PM

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity –– Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II

MEIP

4 minute read

Initial Phase 1 Dose Escalation Data For ORIC-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development At The 65th American Society Of Hematology Annual Meetin…

By Benzinga Newsdesk

December 11, 1:05 PM

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose

ORIC

4 minute read

Editas Medicine Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented Today At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar

By Benzinga Newsdesk

December 11, 1:04 PM

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301

EDIT

4 minute read

Disc Presents Initial Data From Ongoing Phase 1b/2 Trial Of DISC-0974 In Patients With Myelofibrosis And Anemia At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 11, 1:03 PM

Substantial, dose-dependent reductions in serum hepcidin and increases in serum ironHematologic response demonstrated by increased hemoglobin levels and reduction in transfusion burdenDISC-0974 was generally

IRON

5 minute read

Nurix Therapeutics Presents Clinical Data From Its Novel Bruton’s Tyrosine Kinase Degrader Programs, NX-5948 And NX-2127, At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 11, 1:02 PM

Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL)Rapid durable complete responses in a heavily pretreated

NRIX

3 minute read

Atara Biotherapeutics Presents Preclinical Data On ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, At The 65th ASH Annual Meeting

By Benzinga Newsdesk

December 11, 1:01 PM

ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T BenchmarkNo Observed Treatment-Related Toxicities or AlloreactivityData

ATRA

4 minute read

Reported December 9, 2023, Blueprint Medicines Announced Data Showcasing Its Commitment To Advance The Scientific Understanding And Treatment Of Systemic Mastocytosis Was Highlighted At 2023 ASH Annual Meeting

By Benzinga Newsdesk

December 11, 10:47 AM

-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership

BPMC

4 minute read

Immix Biopharma Announces 100% Overall Response Rate And 70% Complete Response; 23.7 Months Best Response Duration (Ongoing) For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis Patients At ASH 2023

By Benzinga Newsdesk

December 11, 10:39 AM

100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated

IMMX

4 minute read

Biomea Fusion Presents Achievement Of Minimal Residual Disease Negativity In First Complete Responder From Ongoing Phase I Study Of BMF-219 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia At The 2023 ASH Annual Meeting

By Benzinga Newsdesk

December 11, 10:27 AM

BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia (AML)

BMEA